281 related articles for article (PubMed ID: 27835715)
1. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
Mischoulon D; Shelton RC; Baer L; Bobo WV; Curren L; Fava M; Papakostas GI
J Clin Psychiatry; 2017 Apr; 78(4):449-455. PubMed ID: 27835715
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder.
Iovieno N; Shelton RC; Petrie SR; Cusin C; Fava M; Papakostas GI
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 28749091
[TBL] [Abstract][Full Text] [Related]
3. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
[TBL] [Abstract][Full Text] [Related]
4. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
Papakostas GI; Petersen TJ; Nierenberg AA; Murakami JL; Alpert JE; Rosenbaum JF; Fava M
J Clin Psychiatry; 2004 Feb; 65(2):217-21. PubMed ID: 15003076
[TBL] [Abstract][Full Text] [Related]
5. Ziprasidone augmentation for anxious depression.
Ionescu DF; Shelton RC; Baer L; Meade KH; Swee MB; Fava M; Papakostas GI
Int Clin Psychopharmacol; 2016 Nov; 31(6):341-6. PubMed ID: 27306192
[TBL] [Abstract][Full Text] [Related]
6. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Earley WR; Guo H; Németh G; Harsányi J; Thase ME
Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
[TBL] [Abstract][Full Text] [Related]
7. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
[TBL] [Abstract][Full Text] [Related]
10. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.
Patkar A; Gilmer W; Pae CU; Vöhringer PA; Ziffra M; Pirok E; Mulligan M; Filkowski MM; Whitham EA; Holtzman NS; Thommi SB; Logvinenko T; Loebel A; Masand P; Ghaemi SN
PLoS One; 2012; 7(4):e34757. PubMed ID: 22545088
[TBL] [Abstract][Full Text] [Related]
11. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR
J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
[TBL] [Abstract][Full Text] [Related]
13. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
Papakostas GI; Vitolo OV; Ishak WW; Rapaport MH; Zajecka JM; Kinrys G; Mischoulon D; Lipkin SH; Hails KA; Abrams J; Ward SG; Meisner A; Schoenfeld DA; Shelton RC; Winokur A; Okasha MS; Bari MA; Fava M
J Clin Psychiatry; 2012 Dec; 73(12):1541-7. PubMed ID: 23290327
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
Muscatello MR; Pandolfo G; Micò U; Lamberti Castronuovo E; Abenavoli E; Scimeca G; Spina E; Zoccali R; Bruno A
J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
17. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
18. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
19. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
Keck PE; Reeves KR; Harrigan EP;
J Clin Psychopharmacol; 2001 Feb; 21(1):27-35. PubMed ID: 11199944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
